UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 6, 2009
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Florida
(State or other jurisdiction
of incorporation)
|
|
000-27836
(Commission File Number)
|
|
65-0643773
(IRS Employer
Identification No.) |
| |
|
|
2 Snunit Street
Science Park, POB 455
Carmiel, Israel
|
|
20100 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On July 6, 2009, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing
that it was approached by the U.S. Food and Drug Administration (FDA) and asked to consider
submitting a treatment protocol for the use of prGCD in patients with Gaucher disease in order to
address an expected shortage of the drug Cerezyme®. A copy of the press release is attached
hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
| (d) |
|
Exhibits |
| |
| 99.1 |
|
Press release dated July 6, 2009. |
2